Shinomiya M, Shirai K, Saito Y, Yoshida S
Second Department of Internal Medicine, School of Medicine, Chiba University, Japan.
Eur J Clin Pharmacol. 1993;45(4):343-6. doi: 10.1007/BF00265952.
The relationship between the content of probucol in plasma and lipid lowering was studied after administration of probucol. The study group consisted of 44 patients with Type II hyperlipidaemia (mean age 56 y). Total cholesterol level was decreased from 293 to 232 mg.dl-1 by the administration of probucol. The plasma probucol concentration was 2.03 mg.dl-1 after 4 weeks of administration of 500 mg b.d. Although there was no relationship between the change in total cholesterol and the plasma probucol, a linear relation was observed between the decrease in LDL-cholesterol concentration and the probucol concentration in LDL. Neither the VLDL nor the HDL-probucol content were related to the magnitude of the decrease in lipoprotein cholesterol. The present study has demonstrated that an increase in the probucol content in LDL was associated with a decrease in plasma LDL-cholesterol.
在给予普罗布考后,研究了血浆中普罗布考含量与降脂作用之间的关系。研究组由44例II型高脂血症患者组成(平均年龄56岁)。给予普罗布考后,总胆固醇水平从293mg/dl降至232mg/dl。在每日两次服用500mg普罗布考4周后,血浆普罗布考浓度为2.03mg/dl。虽然总胆固醇的变化与血浆普罗布考之间没有关系,但观察到低密度脂蛋白胆固醇浓度的降低与低密度脂蛋白中普罗布考浓度之间存在线性关系。极低密度脂蛋白和高密度脂蛋白中的普罗布考含量均与脂蛋白胆固醇降低的幅度无关。本研究表明,低密度脂蛋白中普罗布考含量的增加与血浆低密度脂蛋白胆固醇的降低有关。